GlassScriptPhysician profile
Christian Smith
NPI 1134125511
$153,418.12
in general payments reported to CMS, 2019-2025
39 companies · $1,084 in 2025
The $1,084 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $900 · 2020: $484 · 2021: $685 · 2022: $130K · 2023: $15K · 2024: $4,889 · 2025: $1,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $17K · Food and Beverage: $3,175 · Travel and Lodging: $582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $17,487.07 |
| Food and Beverage | $3,175.45 |
| Travel and Lodging | $581.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Linvatec Corporation | $147,276.79 | 2022-2024 | Avenger Radial Head, +4 Stems |
| Stryker Corporation | $1,562.86 | 2019-2024 | Prostep, N/A, Prophecy |
| Kerecis Limited | $1,420.42 | 2023-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Organogenesis INC. | $434.01 | 2019-2024 | Puraply |
| Treace Medical Concepts, INC. | $413.51 | 2025 | |
| Paratek Pharmaceuticals, INC. | $258.30 | 2020-2024 | Nuzyra |
| Zyla Life Sciences, INC. | $253.13 | 2019-2020 | |
| Smith+Nephew, INC. | $201.87 | 2020-2025 | Collagenase Santyl, Regranex |
| Kowa Pharmaceuticals America, INC. | $193.51 | 2023 | Seglentis |
| Theramicro, INC. | $151.44 | 2025 | Microvisc |
| Melinta Therapeutics, LLC | $150.13 | 2019 | |
| Bone Support INC. | $144.89 | 2025 | Cerament G, Ceramentbone Void Filler |
| Horizon Therapeutics Plc | $130.23 | 2019-2021 | |
| In2bones USA, LLC | $107.16 | 2021 | |
| Boston Scientific Corporation | $64.34 | 2024 | Wavewriter Alpha Prime 16, Patient Trial Kit |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $56.49 | 2021-2022 | |
| Assertio Therapeutics, INC. | $50.51 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $48.10 | 2023 | Exparel, Iovera |
| Angiodynamics, INC. | $44.41 | 2019 | |
| Gentleman Orthopedic Solutions | $42.19 | 2024 | |
| Innovation Technologies INC | $41.88 | 2025 | Irrisept |
| Paragon 28, INC. | $35.57 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $34.50 | 2022 | |
| Sandoz INC. | $26.88 | 2019-2020 | |
| Arteriocyte Medical Systems, INC. | $24.96 | 2020-2021 | |
| Reprise Biomedical, INC. | $23.87 | 2024 | Miro3d |
| Biotissue Holdings INC. | $22.04 | 2025 | |
| Nabriva Therapeutics, Plc | $21.04 | 2020 | |
| Advanced Oxygen Therapy INC. | $20.42 | 2024 | Topical Oxygen Chamber For Extremities |
| Djo, LLC | $20.07 | 2021 | |
| Sanara Medtech INC. | $19.72 | 2021 | |
| Biocomposites INC | $19.25 | 2024 | |
| Kci USA, INC. | $18.55 | 2023 | Activ.A.C., 3m Coban, V.A.C. Dermatac |
| Integra Lifesciences Corporation | $14.72 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Osiris Therapeutics INC. | $14.63 | 2019 | |
| Orthofix Medical, INC. | $14.51 | 2019 | |
| Grt US Holding, INC. | $14.40 | 2020 | |
| Bioventus LLC | $13.65 | 2024 | Exogen Ultrasound Bone Healing System |
| Merck Sharp & Dohme LLC | $13.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christian Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.